Deliver Lasting Relief from Chronic Rhinitis with RhinAer®

Watch Video
patient suffering from chronic rhinitis RhinAer procedure patient with chronic rhinitis relief

RhinAer  – A Comprehensive, Non-Invasive Solution for Chronic Rhinitis

For many patients struggling with chronic rhinitis, medical management does not provide the long-lasting relief they seek, and they remain tied to tissues and sprays to cope with their daily symptoms.

Most current, in-office rhinitis treatments are not comprehensive solutions, and surgical options like septoplasty, turbinate reduction, or other ablative technologies have mixed patient responses and may not alleviate all symptoms.

Compact and portable, the Aerin® Console and the RhinAer Stylus fit seamlessly into any clinic, office, or hospital environment. RhinAer is a convenient and efficient treatment option to integrate into your practice.

RhinAer® stylus console

RhinAer Treats the Causes of Chronic Rhinitis

RhinAer treats the root causes of rhinorrhea, post-nasal drip, and congestion in a single session.

  • Disrupts posterior nasal nerves (PNN) that trigger rhinitis
  • Treats anatomic contributors to congestion including the full length of the inferior turbinates and septal swell bodies

The RhinAer stylus employs proprietary, temperature-controlled radiofrequency (RF) technology optimized for the nasal airway. Once the stylus is activated, the Aerin System automatically maintains the tip’s target temperature for therapeutic benefit while sparing surrounding tissue, including mucosa.

Patients undergoing the treatment experience minimal discomfort and recovery time.* In a recent study with the Aerin Console, there was no aerosol generation above background levels, thereby enhancing safety for physicians and staff.1

Who Benefits Most from the RhinAer Treatment?

  • Patients with moderate to severe chronic rhinorrhea, post-nasal drip, congestion, and/or chronic clearing of the throat
  • Allergy immunotherapy patients with continued drainage
  • Non-allergic chronic rhinitis patients
  • Post-FESS patients with uncontrolled rhinitis

The RhinAer Advantage

  • Disrupts posterior nasal nerve (PNN) that triggers rhinitis
  • Treats anatomic contributors to congestion including the full length of the inferior turbinates and septal swell bodies
  • Incisionless and can be done under local anesthesia
  • Patients are typically able to return to normal activities the same day

The demonstrated relief your patients with chronic rhinitis deserve

2-Year results from the RhinAer pivotal trial2

RhinAer responder rate at 24 months data

88.2% of patients were classified as responders after achieving ≥30% reduction in rTNSS compared to baseline.

RhinAer rTNSS reduction baseline vs 24 months data

65.5% overall rTNSS reduction with all rTNSS sub-scores (rhinorrhea, nasal congestion, nasal itching, and sneezing) showing statistically significant (p<.001) reduction over baseline at 24 months.

RhinAer 24 month symptom reduction data

At 24-months post-nasal drip and chronic cough symptom scores remained significantly (p<.001) improved from baseline at all follow-up time points.

† The Reflective Total Nose Symptom Score (rTNSS) is a validated patient reported outcome used to describe symptoms of rhinitis. The assessment consists of 4 nasal symptom domains (runny nose [rhinorrhea], itchy nose, sneezing, and stuffiness [nasal congestion]). Each item is rated from 0 (absent) to 3 (severe). The 4 domains are added together to provide an overall score ranging from 0 to 12.

RhinAer delivers symptom improvement in chronic rhinitis of allergic, non-allergic, and unknown etiologies

Treatment resulted in statistically significant mean rTNSS improvements for patients suffering from chronic rhinitis of allergic, non-allergic, and unknown etiologies, (p<0.001)

RhinAer rTNSS baseline and 24 months reduction data

RhinAer is a well-tolerated procedure that can be performed safely to reduce the symptoms of chronic rhinitis

NO serious adverse events related to the device and/or procedure were observed

NO device- or procedure-related headaches were reported in the Pivotal Study through 2 years

Study design: Prospective, multi-center, single-arm study was conducted to evaluate the safety and efficacy of the RhinAer® Stylus (RhinAer) on patients with chronic rhinitis symptoms for at least 6 months duration.

Patients: Initial Pivotal Study included a total of 50 patients treated with RhinAer across five US centers with follow-up at 1-, 3-, 6- and 12-months post-procedure. Thirty-four (34) patients completed extended follow-up through 24 months.

Primary endpoints:

  • Change in rTNSS at baseline and 12 weeks post procedure
  • Percentage of participants with treatment-related adverse events (safety)


Download the full Clinical Summary

RhinAer clinical summary


RhinAer procedure patient


RhinAer Patient

“I feel like I can live again and do things I like to do. I’m not sneezing. I’m not blowing my nose. It’s just amazing."

Request a Demo

* Individual results may vary


  1. LeConte et. al. Aerosol generation with common rhinologic devices: Cadaveric study conducted in a surgical suite. [published online ahead of print 07 August 2020]. Int Forum Allergy Rhinol.
  2. Ehmer D, McDuffie CM, Scurry WC, et al. Temperature-Controlled Radiofrequency Neurolysis for the Treatment of Rhinitis. American Journal of Rhinology & Allergy. 2022;36(1):149-156. doi:10.1177/19458924211033400

1 Console, 2 Powerful Treatments

The RhinAer Stylus plugs into the compact and portable Aerin® Console. The console may also be used with the VivAer® Stylus to treat the entire nasal valve and provide lasting relief for patients suffering from nasal airway obstruction.
Aerin console